Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02134210 |
|
Recruitment Status :
Completed
First Posted : May 9, 2014
Results First Posted : May 13, 2019
Last Update Posted : June 28, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Plaque Psoriasis | Drug: Etanercept Drug: CHS-0214 | Phase 3 |
Pt. 1 is a 12-week randomized, double-blind, active-control, parallel-group, multi-center global study. The primary end point is 75% improvement from baseline according to the Psoriasis Area and Severity Index (PASI-75). Comparing CHS-0214 to Enbrel for efficacy and safety at a dosage of 50mg subcutaneous (Sc) twice weekly.
Pt. 2 is a 40-week randomized, double-blind, active-control, parallel-group, multi-center global study where CHS-0214 and Enbrel dosage is reduced to 50mg Sc weekly for maintenance.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 521 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy) |
| Actual Study Start Date : | June 16, 2014 |
| Actual Primary Completion Date : | July 27, 2015 |
| Actual Study Completion Date : | May 12, 2016 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Enbrel (etanercept)
Enbrel 50mg twice weekly times 12 weeks
|
Drug: Etanercept
Head-to-head comparison
Other Names:
|
|
Experimental: CHS-0214
CHS-0214 50mg twice weekly times 12 weeks
|
Drug: CHS-0214 |
- Proportion of Subjects Achieving PASI-75(75% Improvement in Psoriasis Area and Severity Index) From Baseline at Week 12 [ Time Frame: 12-weeks ]
The Psoriasis Area and Severity Index (PASI) is well established in the medical literature and is internationally the most widely used instrument to assess the severity of Psoriasis.
Proportion of subjects achieving PASI-75 from baseline at Week 12. This was the primary endpoint supporting a Biologics Licensing Application in the US.
- Mean Percent Change in PASI (Psoriasis Area and Severity Index) at 12 Weeks [ Time Frame: 12 Weeks ]Mean percent changed in PASI from baseline (last non-missing value prior to first dose) at Week 12. This was the primary endpoint supporting the Marketing Authorization Application in the EU.
- Mean Percent Change in PASI (Psoriasis Area and Severity Index) From Baseline [ Time Frame: Weeks 4, 8, 12, 24, 36, and 48 ]Mean percent change in PASI from baseline at Weeks 4, 8, 12, 24, 36, and 48
- Number of Participants Who Achieved PASI - 75 (75% Improvement in Psoriasis Area and Severity Index) [ Time Frame: Weeks 4, 8, 12, 24, 36, and 48 ]The proportion of subjects who achieved PASI-75 (75% Improvement in Psoriasis Area and Severity Index) from baseline at Weeks 4, 8, 12, 24, 36, and 48.
- Number of Subjects Who Achieved a 50% Improvement in Psoriasis Area and Severity Index (PASI-50) and a 90% Improvement in PASI (PASI-90) [ Time Frame: Weeks 4, 8, 12, 24, 36, and 48 ]The proportion of subjects who achieved a 50% improvement in Psoriasis Area and Severity Index (PASI-50) and a 90% improvement in PASI (PASI-90) response rates from baseline at Weeks 4, 8, 12, 24, 36, and 48
- Change in PSGA (Physician's Static Global Assessment) of Disease Activity on a Scale of 0 to 5 [ Time Frame: 4, 8, 12, 24, 36, and 48 ]
Change in PSGA (Physician's Static Global Assessment) of disease activity on a scale of 0 to 5 from baseline to Weeks 4, 8, 12, 24, 36, and 48.
Minimum Value: 0 Maximum Value: 5
The PSGA of PsO (Psoriasis) was assessed on a scale of 0 to 5, with 0 indicating no PsO (clear of disease),1 (almost clear), and 2 or higher scores indicating more severe disease. Subjects with a clear (0) or almost clear (1) evaluation were considered PSGA responders.
- The Proportion of Subjects With a Change in a PSGA (Physician's Static Global Assessment) Score = 0 to 1 [ Time Frame: Weeks 4, 8, 12, 24, 36, and 48 ]
The proportion of subjects with a change in a PSGA (Physician's Static Global Assessment) score = 0 to 1, demonstrating clear or almost clear skin at Weeks 4, 8, 12, 24, 36, and 48;
Minimum: 0 Maximum: 1 Subjects with a clear(0) or almost clear(1) evaluation were considered PSGA responders.
- Change in Subject's Global Assessment (SGA) of PsO [ Time Frame: Weeks 4, 8, 12, 24, 36, and 48 ]Change in Subject's Global Assessment (SGA) of PsO from baseline to Weeks 4, 8, 12, 24, 36, and 48. The SGA of PsO was assessed using VAS (visual analog scale in the unit of millimeters) , ranging from 0 (good) to 100 (severe). The SGA was assessed at randomization (Week 0/Day 0) and Weeks 4, 8, 12, 24, 36, and 48, as well as at the Follow-up Visit, if applicable. The change in SGA is the value at baseline minus sum of values at weeks 4, 8, 12, 24, 36, and 48. Since the change in SGA is measured from baseline, a negative value indicates a decrease in overall SGA and better overall assessment of PsO.
- Change in DLQI (Dermatology Life Quality Index) [ Time Frame: Weeks 12, 24, and 48 ]
Change in DLQI (Dermatology Life Quality Index) from baseline to Weeks 12, 24, and 48
The DLQI is a 10-question validated questionnaire that was performed at screening, randomization (Week 0/Day 0), and Weeks 12, 24, and 48. It was calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life was impaired.
- Change in EuroQol 5-Dimension Health Status Questionnaire (EQ-5D) [ Time Frame: Weeks 12, 24, and 48 ]
Change in EuroQol 5-Dimension Health Status Questionnaire (EQ-5D) from baseline to Weeks 12, 24, and 48
The EQ-5D was performed at randomization (Week 0/Day 0), and Weeks 12, 24, and 48. The EQ-5D is a generic (non-disease specific), preference-based health-related quality of life measure based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Rated level can be coded as a number 1, 2, or 3, which indicates having no problems for 1, having some problems for 2, and having extreme problems for 3. As a result, a person's health status can be defined by a 5-digit number, ranging from 11111 (having no problems in all dimensions) to 33333 (having extreme problems in all dimensions).
- Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) [ Time Frame: Weeks 12, 24, and 48 ]HAQ-DI - Scales for each question range from 0-3 (0=without any difficulty; 1=with some difficulty; 2=with much difficulty; 3=Unable to do). The "total" for each category is determined by the highest score (greatest difficulty) for that category. The score for the disability index is the mean of the eight category scores. If more than 2 of the categories or 25% are missing, the scale won't be scored. If fewer than 2 or the categories are missing, the sum of the categories was divided by the number of answered categories.
- Change in Highly Sensitive C-reactive Protein (Hs-CRP; mg/L) [ Time Frame: Weeks 12, 24, and 48 ]
Change in highly sensitive C-reactive protein (hs-CRP; mg/L) from baseline to Weeks 12, 24, and 48 for subjects with PsA (Psoriatic arthritis) only.
Highly sensitive C-reactive protein For subjects with PsA, change in hs-CRP from baseline to Weeks 12, 24, and 48 was assessed.
- The Proportion of Subjects With a Durability of Response at Week 48 [ Time Frame: Weeks 24, 36, and 48 when compared to baseline (Week 0). ]The proportion of subjects with a durability of response during Part 2. Durability of response was defined as the maintenance of the PASI-50 or greater at Weeks 24, 36, and 48 when compared to baseline (Week 0).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female adults
- PsO diagnosis for 6 months
- Active disease: PASI greater than or equal to 12, Physician's Static Global Assessment (PSGA) score greater than or equal to 3 (based on a scale or 0-5),
- Body Surface Area (BSA) involved with PsO greater than or equal to 10%
- Dermatology Life Quality Index (DQLI) greater than or equal to 10
- Previously received phototherapy or systemic non-biologic therapy for PsO
Exclusion Criteria:
- Forms of Psoriasis other than PsO
- Drug induced Psoriasis
- Positive QuantiFERON-tuberculosis (TB) Gold Test
- Presence of significant comorbid conditions
- Chemistry and hematology values outside protocol specified range
- Major systemic infections
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02134210
Show 100 study locations
| Study Director: | Barbara K Finck, M.D. | Coherus Biosciences, Inc. |
| Responsible Party: | Coherus Biosciences, Inc. |
| ClinicalTrials.gov Identifier: | NCT02134210 |
| Other Study ID Numbers: |
CHS-0214-04 |
| First Posted: | May 9, 2014 Key Record Dates |
| Results First Posted: | May 13, 2019 |
| Last Update Posted: | June 28, 2019 |
| Last Verified: | June 2019 |
|
PsO |
|
Psoriasis Skin Diseases, Papulosquamous Skin Diseases Etanercept Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Gastrointestinal Agents Immunosuppressive Agents Immunologic Factors |